• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Champions Oncology Inc. (Amendment)

    5/6/24 7:46:06 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CSBR alert in real time by email
    SC 13D/A 1 nea14-champions_18831.htm NEW ENTERPRISE ASSOCIATES 14, L.P. -- CHAMPIONS ONCOLOGY 13D/A(#1) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Champions Oncology, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    15870P307

    (CUSIP Number)

    Stephanie Brecher

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600

    Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    March 15, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 15870P307

    13D Page 2 of 17 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 14, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,713,720 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,713,720 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,713,720 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.6%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

    CUSIP No. 15870P307

    13D Page 3 of 17 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 14, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,713,720 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,713,720 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,713,720 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.6%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

     CUSIP No. 15870P307

    13D Page 4 of 17 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA 14 GP, LTD

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,713,720 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,713,720 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,713,720 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.6%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    CO

     

       

     

     

      CUSIP No. 15870P307

    13D Page 5 of 17 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Forest Baskett

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,713,720 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,713,720 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,713,720 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.6%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 15870P307

    13D Page 6 of 17 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Anthony A. Florence, Jr.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,713,720 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,713,720 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,713,720 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.6%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 15870P307

    13D Page 7 of 17 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Patrick J. Kerins

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,713,720 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,713,720 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,713,720 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.6%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 15870P307

    13D Page 8 of 17 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Mohamad Makhzoumi

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,713,720 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,713,720 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,713,720 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.6%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 15870P307

    13D Page 9 of 17 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Scott D. Sandell

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,713,720 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,713,720 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,713,720 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.6%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 15870P307

    13D Page 10 of 17 Pages    

     

    Item 1. Security and Issuer.

    This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D originally filed on March 24, 2015, and relates to the common stock, $0.001 par value (the “Common Stock”) of Champions Oncology, Inc. (the “Issuer”) having its principal executive office at One University Plaza, Suite 307, Hackensack, NJ 07601.

     

    Certain terms used but not defined in this Amendment No. 1 have the meanings assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D.

     

    This Amendment No. 1 is being filed to report that the beneficial ownership of the outstanding Common Stock held by the Reporting Persons (as defined below) has decreased by more than 1% as a result of an increase in the number of shares of Common Stock outstanding. 

     

     

     

    Item 2. Identity and Background.

    This statement is being filed by:

     

    (a)  New Enterprise Associates 14, L.P. (“NEA 14”); NEA Partners 14, L.P. (“NEA Partners 14”), which is the sole general partner of NEA 14; and NEA 14 GP, LTD (“NEA 14 LTD” and together with NEA Partners 14, the “Control Entities”), which is the sole general partner of NEA Partners 14; and

     

    (b)  Forest Baskett (“Baskett”), Anthony A. Florence, Jr. (“Florence”), Patrick J. Kerins (“Kerins”), and Scott D. Sandell (“Sandell”) (together, the “Directors”) and Mohamad H. Makhzoumi (“Makhzoumi”), M. James Barrett (“Barrett”), Peter J. Barris (“Barris”), Ryan D. Drant (“Drant”), Krishna S. Kolluri (“Kolluri”), David M. Mott (“Mott”), Peter W. Sonsini (“Sonsini”) and Ravi Viswanathan (“Viswanathan”).

     

    The Directors are the directors of NEA 14 LTD. Makhzoumi is a member of the Executive Committee of NEA Management Company, LLC (the “Executive Committee”).

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of NEA 14, each Control Entity, Kerins and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett and Makhzoumi is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.

     

    The principal business of NEA 14 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 14 is to act as the sole general partner of NEA 14. The principal business of NEA 14 LTD is to act as the sole general partner of NEA Partners 14. The principal business of each of the Directors and the Executive Committee is to manage the Control Entities, NEA 14 and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 14 and NEA Partners 14 are exempted limited partnerships organized under the laws of the Cayman Islands. NEA 14 LTD is an exempted company organized under the laws of the Cayman Islands. Each of the Directors is a United States citizen.

     

    Makhzoumi is a United States citizen.

     

     

     

     

    CUSIP No. 15870P307

    13D Page 11 of 17 Pages    

     

     

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Not applicable.

     

     

    Item 4. Purpose of Transaction.

     

    Not applicable.

     

     

    Item 5. Interest in Securities of the Issuer.

     

    (a)NEA 14 is the record owner of the 1,713,720 shares of Common Stock (the “NEA 14 Shares”), which amount includes 151,220 shares of Common Stock issued upon exercise in full of the Warrant on March 6, 2020 and reflects the 1-for-12 reverse stock split of outstanding shares of Common Stock on August 11, 2015. As the sole general partner of NEA 14, NEA Partners 14 may be deemed to own beneficially the NEA 14 Shares. As the sole general partner of NEA Partners 14, NEA 14 LTD may be deemed to own beneficially the NEA 14 Shares. As members of NEA 14 LTD, each of the Directors may be deemed to own beneficially the NEA 14 Shares. As an individual member of the Executive Committee, which committee has been delegated certain approval rights with respect to dispositions of the NEA 14 Shares, Makhzoumi may also be deemed to own beneficially the NEA 14 Shares.

     

    Each Reporting Person disclaims beneficial ownership of the NEA 14 Shares other than those shares which such person owns of record.

     

    The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on the 13,593,767 shares reported by the Issuer to be outstanding as of March 8, 2024 in the Issuer’s Form 10-Q filed on March 15, 2024.

     

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)Each of Barrett, Barris, Drant, Kolluri, Mott, Sonsini and Viswanathan has ceased to beneficially own five percent (5%) or more of the Issuer’s Common Stock as a result of ceasing to be a director of NEA 14 LTD.

     

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Not applicable. 

     

    Item 7. Material to be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

    CUSIP No. 15870P307

    13D Page 12 of 17 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 6th day of May, 2024.

     

     

     

    NEW ENTERPRISE ASSOCIATES 14, L.P.

     

    By:

    NEA PARTNERS 14, L.P.

    General Partner

     

    By:

    NEA 14 GP, LTD

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Director 

     

    NEA PARTNERS 14, L.P.

     

    By:NEA 14 GP, LTD
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Director

     

      

    NEA 14 GP, LTD

     

    By:          *                                

    Scott D. Sandell

    Director

     

     

     

                     *                        

    M. James Barrett

     

     

                     *                        

    Peter J. Barris

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ryan D. Drant

     

     

     

     

     

    CUSIP No. 15870P307

    13D Page 13 of 17 Pages    

     

     

     

     

                     *                        

    Patrick J. Kerins

     

     

                     *                        

    Krishna S. Kolluri

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    David M. Mott

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

                     *                        

    Ravi Viswanathan

     

     

     

     

     

     

     

     

    EXECUTIVE COMMITTEE: 

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

     

    */s/ Stephanie Brecher           

    Stephanie Brecher

    As attorney-in-fact

     

     

    This Amendment No. 1 to Schedule 13D was executed by Stephanie Brecher on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     
     

     

    CUSIP No. 15870P307

    13D Page 14 of 17 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Champions Oncology, Inc.

     

    EXECUTED this 6th day of May, 2024.

     

     

     

    NEW ENTERPRISE ASSOCIATES 14, L.P.

     

    By:

    NEA PARTNERS 14, L.P.

    General Partner

     

    By:

    NEA 14 GP, LTD

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Director 

     

    NEA PARTNERS 14, L.P.

     

    By:NEA 14 GP, LTD
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Director

     

      

    NEA 14 GP, LTD

     

    By:          *                                

    Scott D. Sandell

    Director

     

     

     

                     *                        

    M. James Barrett

     

     

                     *                        

    Peter J. Barris

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ryan D. Drant

     

     

     

     

    CUSIP No. 15870P307

    13D Page 15 of 17 Pages    

     

     

     

     

                     *                        

    Patrick J. Kerins

     

     

                     *                        

    Krishna S. Kolluri

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    David M. Mott

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

                     *                        

    Ravi Viswanathan

     

     

     

     

     

     

    EXECUTIVE COMMITTEE: 

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

     

    */s/ Stephanie Brecher           

    Stephanie Brecher

    As attorney-in-fact

     

    This Agreement relating to Schedule 13D was executed by Stephanie Brecher on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

     

    CUSIP No. 15870P307

    13D Page 16 of 17 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 1st day of August, 2013. 

     

     

    /s/ M. James Barrett              

    M. James Barrett

     

    /s/ Peter J. Barris                    

    Peter J. Barris

     

    /s/ Forest Baskett                  

    Forest Baskett

     

    /s/ Rohini Chakravarthy       

    Rohini Chakravarthy

     

    /s/ Patrick Chung                   

    Patrick Chung

     

    /s/ Ryan Drant                        

    Ryan Drant

     

    /s/ Anthony A. Florence      

    Anthony A. Florence

     

    /s/ Robert Garland                 

    Robert Garland

     

    /s/ Paul Hsiao                         

    Paul Hsiao

     

    /s/ Patrick J. Kerins                

    Patrick J. Kerins

     

     

     

     

     

     

    CUSIP No. 15870P307

    13D Page 17 of 17 Pages    

     

     

     

    /s/ Suzanne King                   

    Suzanne King

     

    /s/ Krishna S. Kolluri            

    Krishna S. Kolluri

     

    /s/ C. Richard Kramlich         

    C. Richard Kramlich

     

    /s/ Edward Mathers              

    Edward Mathers

     

    /s/ David M. Mott                 

    David M. Mott

     

    /s/ John M. Nehra                  

    John M. Nehra

     

    /s/ Charles W. Newhall III    

    Charles W. Newhall III

     

    /s/ Jason R. Nunn                  

    Jason R. Nunn

     

    /s/ Jon Sakoda                       

    Jon Sakoda

     

    /s/ Scott D. Sandell                

    Scott D. Sandell

     

    /s/ Peter W. Sonsini              

    Peter W. Sonsini

     

    /s/ A. Brooke Seawell            

    A. Brooke Seawell

     

    /s/ Ravi Viswanathan            

    Ravi Viswanathan

     

    /s/ Paul E. Walker                  

    Paul E. Walker

     

    /s/ Harry Weller                     

    Harry Weller

     

     

     

     

     

     

    Get the next $CSBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CSBR

    DatePrice TargetRatingAnalyst
    9/12/2024$6.00Hold → Buy
    Craig Hallum
    More analyst ratings

    $CSBR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/17/25 11:03:52 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/11/25 4:32:41 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      12/16/24 4:16:03 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Financials

    Live finance-specific insights

    See more
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

      HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.First Quarter Highlights:Total revenue increased 12% to $14.1 millionMargin improved to 50%Adjusted EBITDA of $2.0 millionNet income of $1.3 millionRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided

      9/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Breitfeld Philip P. disposed of 4,150 shares, decreasing direct ownership by 42% to 5,717 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      4/2/25 4:20:36 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Breitfeld Philip P.

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 12:14:09 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sidransky David

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 11:47:41 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Champions Oncology upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Champions Oncology from Hold to Buy and set a new price target of $6.00

      9/12/24 9:23:16 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roth Capital reiterated coverage on Champions Oncology with a new price target

      Roth Capital reiterated coverage of Champions Oncology with a rating of Buy and set a new price target of $16.00 from $13.50 previously

      3/15/21 10:03:32 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mendelson Daniel Newman bought $6,500 worth of shares (1,000 units at $6.50), increasing direct ownership by 0.51% to 198,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/16/24 11:45:44 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $12,540 worth of shares (2,000 units at $6.27), increasing direct ownership by 1% to 197,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/12/24 12:47:07 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $18,577 worth of shares (2,944 units at $6.31), increasing direct ownership by 2% to 195,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/11/24 10:57:35 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Leadership Updates

    Live Leadership Updates

    See more
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces the Addition of Brady Davis as President

      HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth."We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology. Brady has deep healthcare, data and oncology-specific experience and has a proven track record of building products and solutions that align with customer needs," stated Ronnie Morris, CEO of Champions Oncology.Mr. Davis brings more than 25 years of international experience leading medical

      10/17/23 8:30:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces Addition to Board of Directors

      HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors. Rob is an experienced global life sciences and healthcare executive with more than 15 years of experience. His appointment will help guide the company's efforts to accelerate the development of its data platform for use in drug discovery. The Company also announced the resignation of current board member Abba Poliakoff. Joel Ackerman, Chairman of the Board of Directors commented

      2/22/21 9:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.

      SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      11/14/24 9:53:10 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Champions Oncology Inc. (Amendment)

      SC 13D/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      5/6/24 7:46:06 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Champions Oncology Inc.

      SC 13G - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      2/12/24 9:12:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care